MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer
Slightly above 67% of MorphoSys' investor base is looking to short. The analysis of current outlook of investing in MorphoSys AG ADR suggests that many traders are alarmed regarding MorphoSys' prospects. MorphoSys' investing sentiment overview a quick insight into current market opportunities from investing in MorphoSys AG ADR. Many technical investors use MorphoSys AG ADR stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
MorphoSys |
Novartis is in advanced talks to acquire MorphoSys and appears to be beating out Incyte Corporation which has also made an offer to acquire MorphoSys. MorphoSys produces a lymphoma drug, Monjuvi, sold as part of a profit-sharing agreement with Incyte, which saw net product sales of 92 million in 2023. MorphoSys also is developing Pelabresib, an inhibitor of proteins involved in the development and progression of myelofibrosis.
Read at benzinga.com
 |
MorphoSys Fundamental Analysis
We analyze MorphoSys' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MorphoSys using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MorphoSys based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
MorphoSys is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
MorphoSys AG ADR Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MorphoSys stock to make a market-neutral strategy. Peer analysis of MorphoSys could also be used in its relative valuation, which is a method of valuing MorphoSys by comparing valuation metrics with similar companies.
Peers
MorphoSys Related Equities
| IMRX | Immuneering Corp | 6.88 | ||||
| MRSN | Mersana Therapeutics | 5.63 | ||||
| LYRA | Lyra Therapeutics | 5.56 | ||||
| NVCT | Nuvectis Pharma | 3.98 | ||||
| KRON | Kronos Bio | 2.17 | ||||
| VTYX | Ventyx Biosciences | 2.15 | ||||
| GOSS | Gossamer Bio | 1.19 | ||||
| ACLX | Arcellx | 0.08 | ||||
| MLYS | Mineralys Therapeutics, | 0.39 | ||||
| PMVP | Pmv Pharmaceuticals | 0.66 | ||||
| RLYB | Rallybio Corp | 1.09 | ||||
| ELVN | Enliven Therapeutics | 1.50 | ||||
| GLUE | Monte Rosa | 2.22 | ||||
| EWTX | Edgewise Therapeutics | 3.10 | ||||
| IMCR | Immunocore Holdings | 3.44 | ||||
| GBIO | Generation Bio | 3.60 | ||||
| IPSC | Century Therapeutics | 3.70 | ||||
| REPL | Replimune | 4.14 | ||||
| CCCC | C4 Therapeutics | 5.25 | ||||
| PCVX | Vaxcyte | 5.61 | ||||
| CGEM | Cullinan Oncology | 6.82 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Consideration for investing in MorphoSys Stock
If you are still planning to invest in MorphoSys AG ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MorphoSys' history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |